Atrial fibrillation is a very common arrhythmia whose prevalence is expected to increase significantly as the population ages. The associated stroke risk is a major cause of morbidity and mortality. Stroke prevention by anticoagulation carries its own risks, leading to the search for alternative strategies. Multiple techniques have been developed to exclude the left atrial appendage (the main source of thromboembolism in atrial fibrillation) from the circulation. Such techniques offer the hope of stroke prevention without the risks of anticoagulation. This article describes the percutaneous approaches being currently performed in the United States. Particular emphasis is placed on the use of transesophageal echocardiography to guide these procedures.
ChughSSHavmoellerRNarayananKet al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847.
2.
BallJCarringtonMJMcMurrayJJStewartS.Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807-1824.
3.
WolfPAAbbottRDKannelWB.Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med. 1987;147:1561-1564.
4.
WolfPAAbbottRDKannelWB.Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983-988.
5.
KimuraKMinematsuKYamaguchiT; Japan Multicenter Stroke Investigators’ Collaboration (J-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2005;76:679-683.
6.
SussmanMMenzinJLinIet al. Impact of atrial fibrillation on stroke-related healthcare costs. J Am Heart Assoc. 2013;2:e000479.
7.
JanuaryCTWannLSAlpertJSet al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-2104.
8.
KirchhofPBenussiSKotechaDet al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50:e1-e88.
9.
EckmanMHCosteaAAttariMet al. Atrial fibrillation decision support tool: population perspective. Am Heart J. 2017;194:49-60.
10.
HammersleyDSignyM.Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era. Ther Adv Chronic Dis. 2017;8:165-176.
11.
HylekEMHeldCAlexanderJHet al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014;63:2141-2147.
12.
De CaterinaRAnderssonUAlexanderJHet al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2016;175:175-183.
13.
Esteve-PastorMARivera-CaravacaJMRoldanVet al. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in “real-world” atrial fibrillation patients: a comparison with optimally acenocoumarol anticoagulated patients. Int J Cardiol. 2018;254:125-131.
14.
PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGY.A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.
15.
Esteve-PastorMARivera-CaravacaJMShantsilaARoldanVLipGYHMarinF.Assessing bleeding risk in atrial fibrillation patients: comparing a bleeding risk score based only on modifiable bleeding risk factors against the HAS-BLED score. The AMADEUS trial. Thromb Haemost. 2017;117:2261-2266.
16.
KimMH.Shared risk factors for anticoagulation in nonvalvular atrial fibrillation: a dilemma in clinical decision making. J Am Coll Cardiol. 2014;63:2148-2150.
17.
MauraGBillionnetCAllaFGagneJJParienteA.Comparison of treatment persistence with dabigatran or rivaroxaban versus vitamin K antagonist oral anticoagulants in atrial fibrillation patients: a competing risk analysis in the French National Health Care Databases. Pharmacotherapy. 2018;38:6-18.
18.
StoddardMFDawkinsPRPrinceCRAmmashNM.Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographics study. J Am Coll Cardiol. 1995;25:452-459.
19.
SalzbergSPEmmertMYCaliskanE.Surgical techniques for left atrial appendage exclusion. Herzschrittmacherther Elektrophysiol. 2017;28:360-365.
20.
DawsonAGAsopaSDunningJ.Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion?Interact Cardiovasc Thorac Surg. 2010;10:306-311.
21.
EmmertMYPuippeGBaumullerSet al. Safe, effective and durable epicardial left atrial appendage clip occlusion in patients with atrial fibrillation undergoing cardiac surgery: first long-term results from a prospective device trial. Eur J Cardiothorac Surg. 2014;45:126-131.
22.
CaliskanESahinAYilmazMet al. Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. Europace. 2018; 20: e105-e114. doi:10.1093/europace/eux211.
23.
EllisCRAznaurovSGPatelNJet al. Angiographic efficacy of the Atriclip left atrial appendage exclusion device placed by minimally invasive thoracoscopic approach. JACC Clin Electrophysiol. 2017;3:1356-1365.
24.
GloeklerSSawJKoskinasKCet al. Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. Int J Cardiol. 2017;249:234-246.
25.
VainribAFHarbSCJaberWet al. Left atrial appendage occlusion/exclusion: procedural image guidance with transesophageal echocardiography. J Am Soc Echocardiogr. 2018;31:454-474.
26.
BasmanCParmarYJKronzonI.Intracardiac echocardiography for structural heart and electrophysiological interventions. Curr Cardiol Rep. 2017;19:102.
27.
LacomisJMGoiteinODeibleCet al. Dynamic multidimensional imaging of the human left atrial appendage. Europace. 2007;9:1134-1140.
28.
JeongWKChoiJHSonJPet al. Volume and morphology of left atrial appendage as determinants of stroke subtype in patients with atrial fibrillation. Heart Rhythm. 2016;13:820-827.
29.
TeunissenCHabetsJVelthuisBKCramerMJLohP.Double-contrast, single-phase computed tomography angiography for ruling out left atrial appendage thrombus prior to atrial fibrillation ablation. Int J Cardiovasc Imaging. 2017;33:121-128.
30.
Di BiaseLSantangeliPAnselminoMet al. Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60:531-538.
31.
GoldbergYHGordonSCSpevackDMGordonGM.Disparities in emptying velocity within the left atrial appendage. Eur J Echocardiogr. 2010;11:290-295.
32.
HandkeMHarloffAHetzelAOlschewskiMBodeCGeibelA.Left atrial appendage flow velocity as a quantitative surrogate parameter for thromboembolic risk: determinants and relationship to spontaneous echocontrast and thrombus formation—a transesophageal echocardiographic study in 500 patients with cerebral ischemia. J Am Soc Echocardiogr. 2005;18:1366-1372.
33.
HerringNPageSPAhmedMet al. The prevalence of low left atrial appendage emptying velocity and thrombus in patients undergoing catheter ablation for atrial fibrillation on uninterrupted peri-procedural warfarin therapy. J Atr Fibrillation. 2013;5:761.
34.
WoodsTDPatelA.A critical review of patent foramen ovale detection using saline contrast echocardiography: when bubbles lie. J Am Soc Echocardiogr. 2006;19:215-222.
35.
DeeganRJEagleS.Incidental finding of a double interatrial septum in a patient undergoing atrial fibrillation ablation. CASE. 2018;2:92-94.
36.
HahnRTAbrahamTAdamsMSet al. Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. Anesth Analg. 2014;118:21-68.
37.
BarberoUHoSY.Anatomy of the atria: a road map to the left atrial appendage. Herzschrittmacherther Elektrophysiol. 2017;28:347-354.
38.
ReddyVYDoshiSKKarSet al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70:2964-2975.
LandmesserUSchmidtBNielsen-KudskJEet al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017;13:867-876.
41.
KleineckeCParkJWGoddeMZintlKSchnuppSBrachmannJ.Twelve-month follow-up of left atrial appendage occlusion with Amplatzer Amulet. Cardiol J. 2017;24:131-138.
42.
OsmancikPTousekPHermanDet al. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study). Am Heart J. 2017;183:108-114.
43.
TzikasAGafoorSMeerkinDet al. Left atrial appendage occlusion with the AMPLATZER Amulet device: an expert consensus step-by-step approach. EuroIntervention. 2016;11:1512-1521.
44.
LeeRJLakkireddyDMittalSet al. Percutaneous alternative to the Maze procedure for the treatment of persistent or long-standing persistent atrial fibrillation (aMAZE trial): rationale and design. Am Heart J. 2015;170:1184-1194.
45.
GundaSReddyMNathJet al. Impact of periprocedural colchicine on postprocedural management in patients undergoing a left atrial appendage ligation using LARIAT. J Cardiovasc Electrophysiol. 2016;27:60-64.
46.
GianniCDi BiaseLTrivediCet al. Clinical implications of leaks following left atrial appendage ligation with the LARIAT device. JACC Cardiovasc Interv. 2016;9:1051-1057.
47.
YucelGBehnesMBarthCet al. Percutaneous closure of left atrial appendage significantly affects lipidome metabolism. Sci Rep. 2018;8:5894.
48.
FauchierLCinaudABrigadeauFet al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation. J Am Coll Cardiol. 2018;71:1528-1536.
49.
HolmesDRJrDoshiSKKarSet al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65:2614-2623.
50.
AsmaratsLRodes-CabauJ.Percutaneous left atrial appendage closure: current devices and clinical outcomes. Circ Cardiovasc Interv. 2017;10:e005359.
51.
YerasiCLazkaniMKolluruPet al. An updated systematic review and meta-analysis of early outcomes after left atrial appendage occlusion. J Interv Cardiol. 2018;31:197-206.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
